Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
Price:
4.68
USD
9.6%
Market Closed
Market Cap:
$508.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
US |
|
Harbin Electric Corporation Jiamusi Electric Machine Co Ltd
SZSE:000922
|
CN |
|
C&D Property Management Group Co Ltd
HKEX:2156
|
CN |
|
M
|
Metro Retail Stores Group Inc
XPHS:MRSGI
|
PH |
|
C
|
Chalkis Health Industry Co Ltd
SZSE:000972
|
CN |
|
Midea Group Co Ltd
SZSE:000333
|
CN |
|
M
|
MeiHua Holdings Group Co Ltd
SSE:600873
|
CN |
|
Tillys Inc
NYSE:TLYS
|
US |
|
G
|
Gandhar Oil Refinery (INDIA) Ltd
NSE:GANDHAR
|
IN |
|
Fuji Soft Service Bureau Inc
TSE:6188
|
JP |
|
Shenzhen Fastprint Circuit Tech Co Ltd
SZSE:002436
|
CN |
|
Cambricon Technologies Corp Ltd
SSE:688256
|
CN |
|
N
|
NZME Ltd
ASX:NZM
|
NZ |
|
Delta Resources Ltd
XTSX:DLTA
|
CA |
|
JSW Infrastructure Ltd
NSE:JSWINFRA
|
IN |
Relative Value
The Relative Value of one
RCKT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 4.68 USD,
Rocket Pharmaceuticals Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RCKT Relative Value
HIDDEN
Multiples Across Competitors
RCKT Competitors Multiples
Rocket Pharmaceuticals Inc Competitors
Rocket Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
506.9m USD | 0 | -2.2 | -1.5 | -1.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
